Advice

following an abbreviated submission:

icatibant acetate (Firazyr®) is accepted for use within NHSScotland.

Indication under review: symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.

SMC has previously accepted icatibant acetate for use in adults.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of icatibant. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHSScotland.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
icatibant (Firazyr)
SMC ID:
1332/18
Indication:
Symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older (with C1-esterase-inhibitor deficiency).
Pharmaceutical company
Shire Pharmaceuticals
BNF chapter
Respiratory system
Submission type
Abbreviated
Status
Accepted
Date advice published:
07 May 2018